EQ · Equillium, Inc.
Price & Indicators
Up next
Latest filings
Equillium dosed the first subject in its Australian Phase 1 clinical trial of EQ504 on October 26, 2026, triggering a Milestone Closing that produced $20.0 million in aggregate gross proceeds.
Read the 8-KMetrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EQ
this stock
Equillium, Inc.
|
$86.23M | -8.4% | +13.9% | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$134.22B | +16.8% | +46.2% | 30.8 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.4% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +626.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 26, 2026
- This year
- 15
Equillium dosed the first subject in its Australian Phase 1 clinical trial of EQ504 on October 26, 2026, triggering a Milestone Closing that produced $20.0 million in aggregate gross proceeds.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EQ | +0.0% | -12.6% | -33.6% | -12.6% | -8.4% |
| SPY | -0.1% | +1.3% | +5.6% | +1.3% | +13.3% |
| vs SPY | +0.1% | -13.9% | -39.2% | -13.9% | -21.7% |